Medtronic (MDT) is back on investors’ radar after a series of diabetes focused moves and a fresh dividend decision, tying product launches, a potential MiniMed IPO, and a GE HealthCare partnership into one transformation story.

Despite the dividend affirmation and recent diabetes initiatives, Medtronic’s share price momentum has been weak. The stock has recorded a 1 month share price decline of 9.86% and a year to date share price decline of 3.16%. However, the 3 year total shareholder return of 31.50% presents a much stronger longer term picture that recent developments are now being measured against.

If Medtronic’s diabetes push has you thinking about where healthcare tech goes next, it could be a good time to scan 32 healthcare AI stocks for other potential ideas.

With Medtronic’s shares under pressure over the past month, but a 3 year total return of 31.50%, plus fresh diabetes moves and a confirmed dividend, the key question is simple: is the stock undervalued or is future growth already priced in?

Most Popular Narrative: 2.1% Undervalued

According to a widely followed narrative from user Evangelos, Medtronic’s fair value sits around $95 per share versus the recent $93.01 close, putting a modest gap between market price and narrative estimate.

Financial Resilience: Strong cash flow ($5.8B operating cash flow FY2023) supports a dividend yield of ~3.4%, with 46 consecutive years of dividend increases, a track record few medtech peers can match. Attractive valuation metrics (P/E ~16x vs. industry avg. ~20x) suggest undervaluation.

Curious what earnings profile and margin outlook sit behind that fair value, and how a focused medical device model feeds into the cash flow story? The narrative leans heavily on Medtronic’s diversification across four portfolios and the cash generation backing those dividend commitments, while also baking in expectations around future device adoption and pricing power without spelling out every assumption.

Result: Fair Value of $95 (UNDERVALUED)

However, recent product recalls, regulatory delays, or further pressure in the underperforming diabetes unit could quickly challenge the idea that Medtronic is modestly undervalued.

Next Steps

If this all sounds cautiously optimistic, act quickly and test the narrative against the numbers yourself. Start with the 6 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you risk missing opportunities that fit your goals even better, so widen your search and pressure test your thinking.

• Target dependable cash flows by reviewing businesses with strong payouts and balance sheets using our 14 dividend fortresses.
• Hunt for quality at a sensible price by scanning the 47 high quality undervalued stocks that pair fundamentals with potential upside.
• Spot tomorrow’s potential leaders early by checking our screener containing 24 high quality undiscovered gems, where solid financials have not yet attracted wide attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.